Quick answer: Chronic Inflammatory Response Syndrome (CIRS) — a biotoxin-mediated multi-system illness triggered by water-damaged building exposure, Lyme disease, and other biotoxin-producing organisms — affects an estimated 24% of the population who carry HLA-DR genetic variants that impair their ability to clear biotoxins, resulting in years of unrecognized illness across neurological, immune, endocrine, and vascular systems. Dr. Ritchie Shoemaker’s CIRS protocol — validated in over 1,000 published patient outcomes and seven peer-reviewed studies — identifies 13 objective biomarkers that characterize CIRS, enables objective diagnosis distinct from anxiety or hypochondria, and prescribes a sequential 11-step treatment protocol that produces measurable, reproducible recovery across independent clinical sites worldwide.
What Is CIRS? The Biology of Biotoxin Illness
Chronic Inflammatory Response Syndrome is an acquired dysregulation of the innate immune system triggered by exposure to biotoxin-producing organisms — primarily water-damaged buildings (WDB) containing mold species such as Stachybotrys chartarum, Aspergillus, Chaetomium, Penicillium, Wallemia, and actinomycetes bacteria, along with their mycotoxins and microbial volatile organic compounds (MVOCs). CIRS can also be triggered by Borrelia burgdorferi (Lyme disease), Pfiesteria (dinoflagellate in contaminated water), ciguatera fish toxin, and several other biotoxin sources.
The fundamental mechanism: in the 75% of the population with normal HLA-DR immune recognition genes, biotoxins are rapidly processed by antigen-presenting cells, specific antibodies are generated, and the toxins are cleared from the body. In the 24-25% with susceptible HLA-DR variants (particularly HLA-DR 4-3-53, 11-3-52B, 14-5-52B, and others on Shoemaker’s “dreaded genotype” list), biotoxins are not properly presented to T-cells, specific antibodies are never generated, and toxins recirculate indefinitely in the bloodstream — activating the innate immune system in a perpetual state of dysregulation.
The recirculating biotoxins bind to receptors in virtually every organ system, triggering cytokine release that produces the multi-system symptom cluster of CIRS. Unlike allergic reactions that produce IgE-mediated responses, CIRS is driven by innate immune dysregulation — which is why standard allergy testing is completely normal in CIRS patients, and why the illness evades conventional diagnostic frameworks that rely on specific antibody responses as markers of illness.
The CIRS Symptom Cluster: Why This Illness Is Consistently Misdiagnosed
CIRS produces a constellation of symptoms spanning multiple body systems simultaneously — a pattern rarely explained by a single conventional diagnosis, which typically explains why CIRS patients see multiple specialists over years without diagnosis. Shoemaker’s cluster analysis of over 1,000 CIRS patients identified 37 symptoms across 8 clusters that form a statistically distinct pattern:
Fatigue and weakness cluster: Profound fatigue unresponsive to rest; post-exertional fatigue disproportionate to effort; muscle weakness with normal strength testing. Cognitive cluster: Difficulty concentrating and “brain fog”; word-finding difficulties; short-term memory impairment; difficulty with numbers and mathematics previously mastered. Pain cluster: Unusual ice-pick headaches; muscle and joint aches without objective inflammatory markers; morning stiffness; abdominal pain. Autonomic cluster: Temperature dysregulation; night sweats; excessive thirst; static electricity shocks. Neurological cluster: Tingling and numbness in unusual distributions; metallic taste; light sensitivity; blurred vision; mood instability.
The Cluster Analysis Visual Contrast Sensitivity (VCS) test — a computerized visual test measuring contrast detection at specific spatial frequencies — is abnormal in approximately 92% of CIRS patients (sensitivity 92%, specificity 70% — Shoemaker 2010). VCS testing is available online at survivingmold.com and represents the most accessible screening tool for CIRS available to patients and clinicians. A passing VCS result makes active CIRS very unlikely; a failing VCS in the context of building exposure history and symptom cluster strongly suggests CIRS evaluation is warranted.
The 13 CIRS Biomarkers: Objective Evidence for a Contested Diagnosis
One of the most significant clinical contributions of the Shoemaker CIRS framework is the identification of 13 objective laboratory biomarkers that are consistently abnormal in CIRS patients, that normalize with appropriate treatment, and that have been validated across multiple independent clinical sites. These biomarkers transform CIRS from a symptom-based diagnosis into an objectively measurable condition — addressing the legitimate criticism that “chronic mold illness” lacks objective criteria.
Inflammatory and Complement Markers
TGF-beta1 (Transforming Growth Factor beta-1): The most sensitive and consistent CIRS biomarker. TGF-beta1 is elevated above 2380 pg/mL in CIRS and drives regulatory T-cell suppression, fibrotic processes in the lung and kidney, and the profound fatigue characteristic of CIRS. The mechanism: biotoxins directly upregulate TGF-beta1 production from macrophages and T-regulatory cells as part of the dysregulated innate immune response. TGF-beta1 elevation also contributes to the pulmonary fibrosis risk in severe or long-untreated CIRS.
C4a (Complement Split Product): A complement pathway activation fragment that is elevated above 2830 ng/mL in CIRS and fluctuates with WDB re-exposure, making it both a diagnostic and treatment monitoring marker. C4a elevation indicates ongoing complement pathway dysregulation and correlates with symptom intensity. The complement system — a key component of innate immunity — is inappropriately activated by recirculating biotoxins, consuming complement components and producing inflammatory split products that affect vascular permeability and pain signaling.
MMP-9 (Matrix Metalloproteinase-9): Elevated above 332 ng/mL in CIRS. MMP-9 is a protease that degrades extracellular matrix components; its elevation in CIRS reflects increased vascular permeability (causing cytokines to cross into the CNS, contributing to brain fog) and connective tissue remodeling. Elevated MMP-9 in CIRS patients with comorbid hypermobility syndrome (hEDS) may contribute to worsening connective tissue laxity during active CIRS.
Neuropeptide and Hormonal Markers
MSH (Melanocyte-Stimulating Hormone): The most consequential neuropeptide in CIRS, depleted below 35 pg/mL in approximately 95% of untreated CIRS patients. MSH is produced in the hypothalamus from POMC (proopiomelanocortin) and serves as a master regulator of pain, inflammation, immune function, gut motility, and sleep quality. Low MSH explains multiple CIRS features: chronic pain (MSH is endogenous anti-inflammatory and pain-modulating); sleep disruption (MSH regulates deep sleep architecture); gut leakiness (MSH maintains intestinal tight junctions); antibiotic resistance pattern in GI flora (MSH regulates GI immune defense); and susceptibility to MARCoNS colonization (see below).
VIP (Vasoactive Intestinal Polypeptide): Depleted below 23 pg/mL in CIRS, particularly in advanced or pulmonary-predominant cases. VIP is a neuropeptide with potent anti-inflammatory effects in the lung and GI tract, regulating bronchiolar tone, intestinal motility, and immune cell trafficking. VIP depletion contributes to exercise intolerance, breathlessness, and GI dysmotility in CIRS. Shoemaker’s VIP nasal spray (compounded vasoactive intestinal peptide 50 mcg four times daily) is the final step of the CIRS protocol, used only after prior steps have eliminated biotoxin exposure and re-exposure, cleared MARCoNS, and restored other biomarkers.
ACTH and Cortisol: Dysregulated in CIRS through hypothalamic-pituitary-adrenal (HPA) axis disruption driven by neuroinflammation. ACTH is typically low-normal despite low cortisol, reflecting impaired CRH secretion from the hypothalamus — producing a functional hypocortisolism that differs from Addison disease (where both ACTH and cortisol are abnormal in a characteristic ratio). This functional hypocortisolism contributes to the profound fatigue, orthostatic intolerance, and inflammatory amplification of CIRS.
ADH (Antidiuretic Hormone) and Osmolality: ADH is dysregulated in CIRS — typically low or inappropriately low relative to osmolality — producing the characteristic CIRS symptom of excessive thirst with frequent urination despite adequate fluid intake. Serum osmolality is often elevated above 300 mOsm/kg. This ADH dysregulation reflects hypothalamic disruption and contributes to the electrolyte imbalances and cognitive dysfunction of active CIRS.
Vascular and Metabolic Markers
VEGF (Vascular Endothelial Growth Factor): Typically low in CIRS (below 31 pg/mL), reflecting impaired vascular response to tissue hypoxia. Low VEGF in CIRS contributes to reduced oxygen delivery to tissues — particularly during exercise — producing the profound exercise intolerance and fatigue disproportionate to effort. As VEGF normalizes with CIRS treatment, exercise tolerance typically improves as one of the first measurable functional improvements patients notice.
HLA-DR genotyping: While not a “biomarker” in the conventional sense, HLA-DR typing identifies the genetic susceptibility that explains why some individuals develop CIRS from WDB exposure while coworkers or housemates in the same building remain well. Specific HLA-DR haplotypes are associated with increased CIRS severity and resistance to treatment, while others are associated with more favorable treatment response. HLA-DR typing is available through LabCorp and Quest, and is a one-time test providing permanent information about biotoxin susceptibility.
MARCoNS: The Nasal Biofilm Perpetuating CIRS
Multiple Antibiotic Resistant Coagulase Negative Staphylococci (MARCoNS) are bacteria — primarily Staphylococcus epidermidis and related species — that colonize the deep nasal passages (specifically the sphenoid sinuses) in approximately 80% of chronic CIRS patients. MARCoNS are not pathogenic in the conventional sense — they don’t cause acute sinusitis or systemic infection — but they produce exotoxins A and B that cleave the already-depleted MSH (melanocyte-stimulating hormone) molecules, perpetuating MSH deficiency and preventing recovery even when biotoxin exposure has been removed.
The CIRS mechanism is circular: biotoxin exposure causes inflammation that depletes MSH; low MSH impairs nasal immune defense allowing MARCoNS colonization; MARCoNS exotoxins cleave residual MSH, perpetuating its deficiency; MARCoNS biofilm — resistant to standard antibiotics including those that reach the mucosa — cannot be eradicated without biofilm-disrupting protocols. This is why CIRS patients who leave WDB exposure and eliminate biotoxin sources fail to recover without addressing MARCoNS: the nasal biofilm maintains the MSH-depleting cycle independently of ongoing biotoxin exposure.
MARCoNS diagnosis: nasal culture from a deep nasal swab using specialized transport media sent to Microbiology Dx (the only CLIA-certified laboratory with validated MARCoNS culture and sensitivity testing). The culture report identifies the specific antibiotic resistance profile and tests BEG spray (Bactroban 0.2% + EDTA + gentamicin nasal spray, compounded) and ReSine intranasal spray sensitivity. Treatment: BEG spray twice daily for 30 days is first-line; if BEG-resistant, alternative compounded nasal sprays based on sensitivity testing are prescribed. Re-testing at 30 days confirms eradication before proceeding to later CIRS protocol steps.
The Shoemaker CIRS Protocol: Sequential 11-Step Treatment
The CIRS protocol is strictly sequential — each step must be completed before proceeding to the next. Jumping ahead (e.g., using VIP before clearing MARCoNS, or starting binders before removing biotoxin exposure) produces incomplete results or paradoxical worsening. This sequential requirement is based on the pathophysiological cascade: each step removes or corrects a specific bottleneck in the CIRS mechanism before the next bottleneck is addressable.
Steps 1-3: Remove Exposure, Bind Biotoxins, Clear MARCoNS
Step 1: Remove from biotoxin exposure. The sine qua non of CIRS treatment. Without eliminating ongoing WDB exposure, no subsequent step produces durable benefit. This may require: professional Environmental Relative Moldiness Index (ERMI) testing of all regularly occupied buildings (home and workplace); remediation of confirmed WDB buildings meeting ERMI score criteria (<2 ERMI typical target); or building abandonment when remediation is not feasible or affordable. The HERTSMI-2 score (a subset of the ERMI using the 5 most dangerous mold species) above 11 indicates a building unsafe for CIRS patients. This step is often the most difficult psychologically and economically but is non-negotiable for recovery.
Step 2: Binder therapy to clear recirculating biotoxins. Cholestyramine (CSM, 4g four times daily between meals) is the most established CIRS binder — it binds mycotoxins, Lyme biotoxins, and ciguatera toxin in the GI tract, preventing enterohepatic recirculation. Welchol (colesevelam 625 mg, 3 tabs twice daily) is an alternative for CSM-intolerant patients with equivalent efficacy demonstrated in Shoemaker’s studies. Activated charcoal and bentonite clay are used by some practitioners as adjunctive binders, though with less CIRS-specific evidence. Binder therapy is continued throughout the protocol and remains a mainstay of relapse prevention during incidental re-exposures.
Step 3: Eradicate MARCoNS. After removing biotoxin exposure and beginning binder therapy, MARCoNS nasal biofilm is the primary remaining obstacle to MSH recovery. BEG spray 2-3 sprays per nostril twice daily for 30 days, with re-culture at day 30 confirming eradication. Approximately 15-20% of MARCoNS cases require multiple BEG courses or alternative compounded formulations. MSH levels do not reliably recover until MARCoNS is eradicated.
Steps 4-7: Correct Downstream Hormonal and Inflammatory Cascade
Step 4: Correct antigliadin antibodies if elevated (indicating gluten sensitivity driven by intestinal permeability from low MSH). Gluten elimination for 3 months followed by reassessment. Step 5: Correct MMP-9 elevation using fish oil (omega-3 EPA+DHA 2-4 g daily) and/or high-dose rosuvastatin (short-term) — MMP-9 normalization is prerequisite for VIP later in the protocol because elevated MMP-9 would transport VIP across an abnormally permeable blood-brain barrier into the CNS. Step 6: Correct elevated VEGF through structured hyperbaric oxygen therapy (when VEGF is below threshold) or simply through ongoing biotoxin clearance, as VEGF often normalizes spontaneously with steps 1-3. Step 7: Correct elevated C3a if elevated — using a low amylose/low mycotoxin diet (avoiding grains, high-amylose foods that feed certain gut pathogens amplifying inflammation) and treating any detected Lyme disease or other ongoing biotoxin sources.
Steps 8-11: Hormonal Restoration and VIP
Step 8: Correct ADH/osmolality dysregulation using DDAVP (desmopressin) if ADH is definitively low with elevated osmolality — used intermittently under close electrolyte monitoring. Many patients correct spontaneously with steps 1-7. Step 9: Correct testosterone/DHEA deficiency if present — cortisol-cortisone shuttle normalization often recovers with MSH restoration. Bioidentical testosterone or DHEA under monitoring if hormonal deficiency persists. Step 10: Correct cortisol dysregulation — functional hypocortisolism typically normalizes with MSH recovery; pharmaceutical cortisol support only if HPA axis remains impaired after prior steps.
Step 11: VIP nasal spray (Vasoactive Intestinal Peptide, 50 mcg four times daily, compounded). VIP is the most powerful CIRS treatment tool and the culminating step — but it is contraindicated until all prior steps are complete. VIP restores neuropeptide levels including MSH (the VIP/MSH axis is bidirectional), normalizes TGF-beta1, reduces pulmonary inflammation, corrects VEGF, and produces dramatic symptomatic improvement in most patients who reach this step. Used prematurely (before MARCoNS is cleared, before binders are established, or during ongoing WDB exposure), VIP can significantly worsen symptoms. When used appropriately, VIP often produces the most dramatic single treatment response in the CIRS protocol.
Mold-Related Illness Beyond CIRS: Mycotoxin Testing and Environmental Medicine
Not all mold-related illness fits the Shoemaker CIRS framework. Individuals with normal HLA-DR genotypes may still experience significant health effects from mycotoxin exposure through direct toxic mechanisms — independent of the innate immune dysregulation pathway that drives CIRS in genetically susceptible individuals.
Mycotoxin Direct Toxicity
Major mycotoxins found in WDB include: trichothecenes (produced by Stachybotrys, Fusarium) — among the most acutely toxic fungal metabolites, with documented immunosuppressive and cytotoxic effects at low concentrations; ochratoxin A (produced by Aspergillus and Penicillium) — a nephrotoxin and probable human carcinogen (IARC Group 2B) found in contaminated grain foods and WDB; aflatoxin B1 (Aspergillus flavus/parasiticus) — the most potent natural carcinogen known, a Group 1 IARC carcinogen primarily from food contamination but found in WDB with moisture intrusion; and mycophenolic acid (Penicillium species) — immunosuppressive at doses achievable in heavily contaminated environments.
Urine mycotoxin testing (RealTime Laboratories, Great Plains Laboratory GPL-MycoTOX) detects and quantifies mycotoxins in urine, providing evidence of exposure and body burden in individuals without the CIRS innate immune dysregulation profile. Positive mycotoxin testing in the absence of CIRS biomarker profile directs intervention toward enhanced biotoxin elimination: high-fiber diet, increased hydration, glutathione support (NAC 600 mg twice daily, liposomal glutathione 500-1000 mg daily), activated charcoal binders, and sauna therapy with mineral replacement for enhanced sweat-based elimination.
Building Testing: ERMI and HERTSMI-2
The Environmental Relative Moldiness Index (ERMI) uses DNA-based mold quantification (MSQPCR) to identify and quantify 36 mold species in settled dust samples, producing an ERMI score that ranks relative mold burden compared to a national reference population of homes. The ERMI was developed by the EPA and NIH, and Shoemaker’s CIRS research uses ERMI scores above 2 as an indication of a potentially unsafe building for genetically susceptible individuals.
The HERTSMI-2 (Health Effects Roster of Type-Specific Formers of Mycotoxins and Inflammagens — 2nd version) is a simplified subset of the ERMI using only the 5 most clinically significant mold species (Stachybotrys chartarum, Aspergillus penicillioides, Aspergillus versicolor, Wallemia sebi, Chaetomium globosum) weighted by clinical significance. A HERTSMI-2 score above 11 indicates a building unsafe for CIRS patients; scores of 4-10 require clinical judgment based on patient sensitivity. The HERTSMI-2 can be calculated from a standard ERMI test result, providing a practical safety threshold for re-occupancy decisions in CIRS recovery.
Functional Nutrition and Lifestyle Support in CIRS
While the Shoemaker protocol provides the core biomarker-driven treatment framework, functional nutrition and lifestyle interventions support detoxification, mitochondrial function, and immune restoration throughout treatment.
Low-amylose, low-mycotoxin diet: Shoemaker recommends avoiding high-amylose foods (whole grains, legumes, starchy vegetables) because amylose promotes growth of gut pathogens that amplify C3a and other CIRS-relevant inflammatory markers. Additionally, many grains — particularly corn, wheat, peanuts — have high mycotoxin contamination rates from field mold, creating ongoing oral mycotoxin exposure that competes with binder therapy. A meat, fish, eggs, non-starchy vegetables, and low-sugar fruit dietary pattern minimizes ongoing mycotoxin ingestion while providing complete nutrition.
Glutathione support: Glutathione is the liver’s primary mycotoxin conjugation enzyme, and CIRS typically produces glutathione depletion from chronic inflammatory burden. NAC 600 mg twice daily (glutathione precursor); alpha-lipoic acid 300 mg twice daily (recycles glutathione from oxidized form); milk thistle (silymarin 140 mg three times daily — Hepatology evidence for hepatoprotection and Phase II detoxification enzyme induction); and liposomal glutathione 500-1000 mg daily bypass the oral absorption limitations of standard glutathione supplements.
Sleep hygiene and circadian optimization: MSH depletion in CIRS disrupts deep sleep architecture, creating a vicious cycle where poor sleep amplifies neuroinflammation and cytokine production that further depletes MSH. Circadian light hygiene (morning bright light, evening darkness), sleep temperature optimization (18-20 degrees Celsius), and avoidance of EMF devices in the bedroom support endogenous MSH recovery as treatment progresses.
Infrared sauna: Far-infrared sauna (40-50 minutes at 120-140 degrees F, two to three times weekly) enhances sweat-based mycotoxin elimination, activates heat shock proteins with anti-inflammatory effects, improves mitochondrial biogenesis, and supports the autonomic regulation disrupted by CIRS. Sauna must be preceded by adequate hydration and electrolyte intake to prevent the hypovolemia that exacerbates CIRS orthostatic symptoms. In patients with POTS comorbidity, sitting sauna (not standing) at lower temperatures with monitoring is the safer protocol.
If you have been told your symptoms are medically unexplained, or if you recognize the multi-system symptom pattern of CIRS following water-damaged building exposure, mold, Lyme disease, or other biotoxin sources, call our office at (810) 206-1402 to schedule a CIRS evaluation. Objective biomarker testing distinguishes CIRS from other conditions and enables the precise, sequential treatment protocol that produces documented recovery across multiple validated clinical sites.
Frequently Asked Questions
How do I know if my house has toxic mold?
The most reliable test is ERMI (Environmental Relative Moldiness Index) using settled dust samples analyzed by MSQPCR — available through Mycometrics or EnviroBiomics. An ERMI score above 2 is potentially unsafe for CIRS-susceptible individuals; a HERTSMI-2 score above 11 (calculated from the ERMI) indicates a building unsafe for CIRS patients regardless of visible mold. Professional water damage assessment — identifying areas of past or current moisture intrusion, roof leaks, plumbing failures, or inadequate vapor barriers — complements testing, since mold can grow behind walls and above ceilings without visible signs. Visual inspection alone misses approximately 40-50% of WDB problems.
Can you have CIRS without visible mold in your home?
Yes. Water-damaged buildings with past moisture events — even if dried and remediated years before — can harbor persistent mold colonization in wall cavities, subfloor materials, HVAC systems, and insulation that is completely invisible to visual inspection. Mycotoxins also persist in building materials, dust, and furnishings for years after the moisture source is resolved. ERMI dust testing detects the DNA of mold species regardless of visible growth and is far more sensitive than visual inspection or air sampling (which only detects actively sporulating mold, not dormant colonies or embedded mycotoxins).
Is CIRS the same as mold allergy?
No. Mold allergy is an IgE-mediated hypersensitivity response producing typical allergic symptoms (sneezing, rhinorrhea, wheezing) that responds to antihistamines. CIRS is an innate immune dysregulation driven by biotoxin recirculation in genetically susceptible individuals — standard allergy testing is typically negative in CIRS, and antihistamines do not address the core mechanism. CIRS requires biomarker-guided sequential treatment protocol, not allergy management. The HLA-DR genotype explains susceptibility: allergic individuals have normal HLA-DR genes and typically clear mold exposure without CIRS; CIRS individuals with susceptible HLA-DR variants cannot generate specific antibodies to clear biotoxins.
How long does CIRS treatment take?
Treatment timeline varies significantly based on duration of illness, number of ongoing exposure sources, MARCoNS colonization resistance, and biomarker severity at baseline. Most patients following the sequential Shoemaker protocol complete the core 11 steps over 6-18 months, with VIP phase (the final, most therapeutic step) typically beginning 3-9 months into treatment after prior steps have normalized prerequisite biomarkers. Patients who identify and eliminate WDB exposure rapidly and complete the protocol without complications often report significant improvement within 3-6 months. Long-untreated CIRS with severe biomarker dysregulation, multiple co-infections, or multiple ongoing exposure sources may require 18-24 months. Relapse prevention — avoiding further WDB exposure, maintaining binder use during incidental exposures, and monitoring biomarkers annually — is a lifetime management priority for HLA-DR susceptible individuals.
Related Articles
- Leaky Gut & Intestinal Permeability Protocol
- Anti-Inflammatory Diet: Foods & Protocol
- Chronic Stress & Cortisol: What It Does to Your Body
Dive Deeper
- Chronic Pain and Inflammation: The Root Cause Protocol That Works Without NSAIDs
- Anxiety: The Physiological Root Causes Your Doctor Isn’t Testing For
- Environmental Toxins & Microplastics: How to Reduce Exposure and Support Detoxification
- Chronic Inflammation: The Silent Driver of Heart Disease, Diabetes, and Alzheimer’s
- Brain Fog: The 8 Root Causes, How to Test for Each, and What Actually Fixes It